Market Research Reports

Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018

112pages
Published Date: 2013-05-07
 

Description




The computational biology market is predicted to have a notable growth owing to its wide use by biotechnology and pharmaceutical companies to reduce the incidences of late stage failures of their drugs and to thereby curb R&D expenditure. Computational biology is also assisting in reducing the extensive use of humans in trials and is therefore useful for pediatric trials, trials on pregnant women and orphan disease research.

This report analyses the global market for computational biology by two main types of studies-cellular modeling and disease modeling. Each of these segments has been further analyzed by various studies with use of simulation, right from drug discovery to drug development. The market has also been bifurcated on the basis of tools which include databases, software and IT infrastructure. The computational biology services market highlights the trend of in-house and contract computational biology. The end users market studies the usage pattern of academic research institutes and commercial industry. All the above mentioned segments are analyzed on the basis of market size in terms of USD million and their forecasts for the period 2012 to 2018 have also been provided. The CAGR (%) for each market segment has been estimated for the forecast period 2012 to 2018, considering 2011 as the base year.
 
Geographically, this market has been divided into four major regions which include North America, Europe, Asia and RoW (Rest of the world). Market sizes, forecasts and % CAGR for each region have been provided. The major drivers, restraints, challenges and growth opportunities and other qualitative dynamics have been considered in the market overview section of this report.

The competitive landscape of this industry has been covered under market share analysis by key players. Our recommendation chapter provides assistance to industry players on ways to enter this market or to establish sustainable competitive advantage.

The global computational biology market is segmented as follows:

Computational Biology Market, By Types
  • Cellular & Biological Simulation
    • Computational Genomics
    • Computational Proteomics
    • Pharmacogenomics
    • Others (Transcriptomics/ Metabolomics)
  • Disease Modeling and Simulation
    • Drug Discovery
      • Target Identification
      • Target Validation
      • Lead Discovery
      • Lead Optimization
  • Drug Development
    • Preclinical
      • Pharmacokinetics
      • Pharmacodynamics
  • Clinical trials
    • Phase I
    • Phase II
    • Phase III
  • Human Body Simulation Software
Computational Biology Market, By Services
  • In-House
  • Contract 
Computational Biology Market, By End Users
  • Academics
  • Industry/ Commercial Players
Computational Biology Market, By Geography
  • North America
  • Europe
  • Asia
  • Rest of the World (RoW)
  • Industry/ Commercial Players

Table of Contents




Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Scope Of The Report
1.4 Research Methodology
      1.4.1 Sources
               1.4.1.1 Secondary Research
               1.4.1.2 Primary Research
               1.4.1.3 Models
1.5 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Computational Biology Market (2011 & 2018)
2.2 Global Computational Biology Market, by Types, 2011 (USD Million)

Chapter 3 Global Computational Biology Market Dynamics
3.1 Market Overview
3.2 Drivers
      3.2.1 Failure Of Drug Candidates in Late Stage of Clinical Trials
               3.2.1.1 Average Cost to Develop One New Drug (1975 -2011) (USD Million)
               3.2.1.2 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
               3.2.1.3 Reasons For Failure (%) in Phase II & Phase III
      3.2.2 Enhanced Computational Tools
      3.2.3 Improved Government Funding &Industrial Support
3.3 Restraints
      3.3.1 Lack of Standardization
      3.3.2 Non-Verified Predictive Models
3.4 Challenges
      3.4.1 Shortage of Skilled Resources
      3.4.2 Data Storage
3.5 Opportunities
      3.5.1 Cloud Computing
      3.5.2 Modelling And Simulations in Paediatrics Drug Development
3.6 Porters Five Forces Analysis
      3.6.1 Bargaining Power of Suppliers
      3.6.2 Bargaining Power of Buyers
      3.6.3 Threat of New Entrants
      3.6.4 Threat Of Substitutes
      3.6.5 Competitive Rivalry
3.7 Market Attractiveness Analysis
      3.7.1 Market Attractiveness Analysis: Global Computational Biology Market, by Geography
3.8 End User Analysis
      3.8.1 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)

Chapter 4 Global Computational Biology Market, by Applications
4.1 Introduction
      4.1.1 Cellular Modelling and Simulation
               4.1.1.1 Computational Genomics
                          4.1.1.1.1 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
               4.1.1.2 Computational Proteomics
                          4.1.1.2.1 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
               4.1.1.3 Pharmacogenomics
                          4.1.1.3.1 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
               4.1.1.4 Others (Metabolomics/ Transcriptomics)
                          4.1.1.4.1 Global Computational Others (Metabolomics/Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
      4.1.2 Disease Modelling And Simulation Applications / CADD (Computer Aided Drug Design)
              4.1.2.1 Drug Discovery
                         4.1.2.1.1 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.2 Target Identification
                                       4.1.2.1.2.1 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.3 Target Validation
                                       4.1.2.1.3.1 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.4 Lead Identification/Discovery
                                       4.1.2.1.4.1 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.5 Lead Optimization
                                       4.1.2.1.5.1 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
             4.1.2.1 Drug Development
                         4.1.2.1.1 Preclinical
                                       4.1.2.1.1.1 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.2 Clinical Trials
                                       4.1.2.1.2.1 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
                                       4.1.2.1.2.2 Phase I
                                       4.1.2.1.2.3 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
                                       4.1.2.1.2.4 Phase II
                                       4.1.2.1.2.5 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
                                       4.1.2.1.2.6 Phase III
                                       4.1.2.1.2.7 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
                         4.1.2.1.3 Human Body Simulation Software
                                       4.1.2.1.3.1 Global Computational Human Simulation Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Computational Biology Market, by Tools
5.1 Overview
5.2 Database
      5.2.1 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
5.3 IT Infrastructure (Hardware)
      5.3.1 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
5.4 Analysis Software & Services
      5.4.1 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 6 Global Computational Biology Market, by Services
6.1 Overview
6.2 In-House Computational Biology
      6.2.1 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
6.3 External/Contract Computational Biology
      6.3.1 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 7 Global Computational Biology Market, by Geography
7.1 Overview
7.2 North America
      7.2.1 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.3 Europe
      7.3.1 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.4 Asia
      7.4.1 Asia Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.5 ROW
      7.5.1 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 8 Market Share Analysis
8.1 Market Share by Key Players
      8.1.1 Global Computational Biology Market Share Analysis of Key Players, 2011 (%)

Chapter 9 Recommendations
9.1 Success Strategies
      9.1.1 Rigorous Research and Development (R&D) Initiatives
      9.1.2 Investing in Emerging Economies
      9.1.3 Investing in High-End Technologies
      9.1.4 Collaborations, Mergers and Acquisitions
9.2 Barriers to be Considered
      9.2.1 High Cost of Investment

Chapter 10 Company Profiles
10.1 Accelrys
      10.1.1 Company Overview
      10.1.2 Financial Overview
      10.1.3 Product Portfolio And Services
      10.1.4 Business Strategy
      10.1.5 Recent Developments
10.2 Certara
      10.2.1 Company Profile
      10.2.2 Financial Overview
      10.2.3 Product Portfolio And Services
      10.2.4 Business Strategy
      10.2.5 Recent Developments
10.3 Chemical Computing Group Inc.
      10.3.1 Company Profile
      10.3.2 Financial Overview
      10.3.3 Product Portfolio
      10.3.4 Business Strategy
      10.3.5 Recent Developments
10.4 Compugen, Ltd
      10.4.1 Company Profile
      10.4.2 Financial Overview
      10.4.3 Business Strategy
      10.4.4 Recent Developments
10.5 Entelos
      10.5.1 Company Profile
      10.5.2 Financial Overview
      10.5.3 Product Portfolio And Services
      10.5.4 Business Strategy
      10.5.5 Recent Developments
10.6 Genedata AG
      10.6.1 Company Profile
      10.6.2 Financial Overview
      10.6.3 Product Portfolio And Services
      10.6.4 Business Strategy
      10.6.5 Recent Developments
10.7 Insilico Biotechnology AG
      10.7.1 Company Profile
      10.7.2 Financial Overview
      10.7.3 Product Portfolio
      10.7.4 Business Strategy
      10.7.5 Recent Developments
10.8 Leadscope, Inc
      10.8.1 Company Profile
      10.8.2 Financial  Overview
      10.8.3 Product Portfolio
      10.8.4 Business Strategy
      10.8.5 Recent Developments
10.9 Nimbus Discovery LLC
      10.9.1 Company Profile
      10.9.2 Financial Overview
      10.9.3 Product Portfolio
      10.9.4 Business Strategy
      10.9.5 Recent Developments
10.10 Rhenovia  Pharma SAS
      10.10.1 Company Profile
      10.10.2 Financial Overview
      10.10.3 Product Portfolio And Services
      10.10.4 Business Startegy
      10.10.5 Recent Developments
10.11 Schrodinger
      10.11.1 Company Overview
      10.11.2 Financial Overview
      10.11.3 Product Portfolio And Services
      10.11.4 Business Strategy
      10.11.5 Recent Developments
10.12 Simulation Plus, Inc.
      10.12.1 Company Profile
      10.12.2 Financial Overview
      10.12.3 Product Portfolio And Services
      10.12.4 Business Strategy
      10.12.5 Recent Developments

List of Figures

FIG. 1 Global Computational Biology: Market Segmentation
FIG. 2 Global Computational Biology Market, By Types, 2011 (USD Million)
FIG. 3 Average Cost to Develop one New Drug (1975 -2011) (USD Million)
FIG. 4 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
FIG. 5 Reasons for Failure (%) in Phase II & Phase III
FIG. 6 Porter’s Five Forces Analysis for Computational Biology Market
FIG. 7 Market Attractiveness Analysis: Global Computational Biology Market, By Geography
FIG. 8 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)
FIG. 9 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 10 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 11 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 12 Global Computational Others (Metabolomics/ Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
FIG. 13 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
FIG. 14 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 15 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
FIG. 16 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 17 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
FIG. 18 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 19 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 20 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
FIG. 21 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
FIG. 22 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
FIG. 23 Global Computational Human Simulation Software Market Revenues, 2010 – 2012 (USD Million)
FIG. 24 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
FIG. 25 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
FIG. 26 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)
FIG. 27 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 28 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 29 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 30 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 31 Asia Computational Biology Market Revenue, 2010 – 2018 (USD Million)
FIG. 32 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 33 Global Computational Biology Market Share Analysis Of Key Players, 2011 (%)
FIG. 34 Annual Revenues: Accelrys, 2009 - 2011 (USD Million)
FIG. 35 Annual Revenue: Compugen, 2010 – 2012 (USD Million)
FIG. 36 Annual Revenues: Simulation Plus, Inc., 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Global Computational Biology Market: Snapshot (2011 & 2018)
TABLE 2 R&D Function by Expenditure (%)
TABLE 3 Global Computational Biology Market Revenues, by Segments, 2010 – 2018 (USD Million)
TABLE 4 Global Cellular Modeling and Biology Simulation Market Revenues, by Types, 2010 – 2018 (USD Million)
TABLE 5 Global Cellular Modeling and Biology Simulation Market Revenues, by Geography, 2010 – 2018 (USD Million)
TABLE 6 Global Disease Modeling and Simulation Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 7 Global Disease Modeling and Simulation Market Revenues, by Geography, 2010 - 2018 (USD Million)
TABLE 8 Global Computational Drug Development Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 9 Software Packages for PBPK Modeling
TABLE 10 Global Computational Biology Market Revenues, by Tools, 2010- 2018 (USD Million)
TABLE 11 Global Computational Services Market Revenues, by Services, 2010- 2018 (USD Million)
TABLE 12 Global Computational Biology Market, by Geography, 2010- 2018 (USD Million)

Enquiry Before Buying




Free Market Analysis




The computational biology market deals with the use of biology and computers for drug discovery and drug development. This is conducted through modeling and simulation models for pharmacokinetics and pharmacodynamics. Rise in late stage drug failure coupled with contraction of innovative drugs has led to huge financial losses to the biotech pharmaceutical companies. It has therefore become imperative for pharmaceutical companies to invest in computational biology. In 2011, the global computational biology market was valued to be USD 760.2 million and is expected to grow at a CAGR of 21.3% from 2012 to 2018. 

Computational biology also helps to reduce extensive use of humans in trials and is therefore useful for pediatric trials, trials on pregnant women and orphan disease research. The drug discovery market accounts to be the largest market for computational biology as its use at this stage helps in reduction of drug failure in the subsequent phase i.e. development phase. Currently, there is a large market of contract service providers of computational biology; nonetheless multinational pharmaceutical companies are setting up their own computational biology centers to fasten the process of drug discovery and development. Governments across the globe are funding infrastructure and academic courses to improve and increase the number of computational biologists. 

Large pharmaceutical companies such as Pfizer, Roche, Novartis, and Sanofi are now exploring this market to have better outcomes of clinical trials. The drugs which have failed in the last stage of clinical trials are also being studied using computational biology to understand and apply its use for other disease indications. Though North America remains the largest market in the world, Asian countries namely India and China are witnessing fast growth and are predicted to emerge as dominating markets in the near future. The major players of this market are Schrödinger, Accelrys, Compugen, Entelos, Rhenovia Pharma and others.

global-computational-biology-market-revenues-by-segments-2010-2018
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research